Rituximab for the treatment of adult-onset IgA vasculitis (Henoch-Schönlein purpura)
Arthritis & Rheumatism Oct 07, 2017
Maritati F, et al. - The purpose of this study is to test the effectiveness and safety of rituximab in a multicentre cohort of patients with adult-onset immunoglobulin A vasculitis (IgAV). The outcome of this study recommends that rituximab is a successful and safe therapeutic alternative for adult-onset IgAV.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
